48,466
edits
Difference between revisions of "Malignant melanoma"
Jump to navigation
Jump to search
→Margin assessment
| Line 220: | Line 220: | ||
*'''I'''ncreased basal melanocytes. | *'''I'''ncreased basal melanocytes. | ||
*'''N'''ests of melanocytes. | *'''N'''ests of melanocytes. | ||
=====Reporting===== | |||
*There is no general agreement on how to report margins in melanoma. | |||
It is suggested that one should: | |||
*Tease try to apart melanoma cells from benign melanocytes. | |||
*Report the clearance of the nearest melanoma cell to the margin. | |||
**Positive margins are when a melanoma cell is inked. | |||
*Use [[immunostain]]s to assist the assessment of difficult cases.<ref name=pmid21797920>{{Cite journal | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref> | |||
**MiTF is considered the preferred marker. | |||
**MART-1 (Melan A) is considered to overestimate melanocytes. | |||
====Subtypes==== | ====Subtypes==== | ||